SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood's stock is trending as investors discuss its potential inclusion in the S&P 500, with the official announcement expected soon. The community is weighing the potential for a short squeeze against the historical trend of stocks dropping after being added to the index. Optimistic traders believe the inclusion, along with upcoming events, will drive the stock higher.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as community members highlight its recent selection by the U.S. Department of Commerce to verify and distribute economic data onchain, marking a significant step for decentralized infrastructure. Discussions revolve around the potential impact of this government partnership and the long-term prospects of Pyth as a leading oracle in the crypto space. Some investors are comparing it to Chainlink and other real-world asset tokens.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending as it joins the S&P 500, sparking excitement and debate about potential short squeezes and future price movement. The community is discussing whether the stock was pumped prior to the announcement and speculating on profit-taking strategies. Some investors express frustration for selling earlier, while others are optimistic about long-term growth.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to its low float, with traders speculating it could be the next stock to experience a significant squeeze. The community is actively discussing its potential for a rapid price increase, drawing comparisons to other low-float stocks that have recently made substantial moves. A recent land sale boosting NAV is also circulating.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch ($IMG.X) is trending as the community rallies around the token's $SOL.X reward system for holders, emphasizing its potential for passive income. Despite some volatility and past challenges, the community highlights its resilience and the arrival of new developers, sparking renewed optimism. Discussions also focus on upcoming events and partnerships, contributing to the token's visibility.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

aTyr Pharma is trending as investors discuss the potential implications of recent inducement grants and upcoming Phase 3 data, with some speculating about the company's confidence in positive results based on hiring activity. Community perspectives are divided, with bullish arguments emphasizing the potential for a successful outcome and high price targets, while bearish viewpoints focus on past trial data and concerns about short selling strategies. The stock's high short interest and upcoming data readout are contributing to increased volatility and active conversation.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond is trending as traders discuss the implications of its new ticker symbol and potential connections to blockchain technology through Tzero, drawing comparisons to past meme stock surges like $GME. The community is actively debating whether this is a fresh start or another fleeting rally, and speculating about possible involvement from figures like Ryan Cohen. Some investors believe Overstock's transition to Bed Bath & Beyond, combined with blockchain assets, could drive a significant turnaround.

Pineapple Financial, Inc. is a Canadian based mortgage technology and brokerage company, which engages in the mortgage brokerage services and technology solutions to Canadian mortgage agents, brokers, sub-brokers, brokerages, and consumers. The company also provides back-office services, together with pre-underwriting support services. The company was founded by Shubha Dasgupta, Kendall Marin, and Charles Andrew Green on October 16, 2015 and is headquartered in North York, Canada.

Pineapple Financial Inc

Pineapple Financial ($PAPL) is trending due to a recently closed $100M private placement and a move into Injective (INJ) tokens, sparking high volatility. The community is buzzing about potential short squeezes and halts, with bulls anticipating further upside and bears cautioning about dilution. Traders are closely watching price action and momentum, with some eyeing new entries while others secure profits.

The Children's Place, Inc. engages in the provision of apparel, footwear, accessories, and other items for children. The firm also designs contracts to manufacture and sell fashionable and value-priced merchandise under the brand names of The Children’s Place, Baby Place, and Gymboree. It operates through The Children’s Place U.S. and The Children’s Place International segments. The Children’s Place U.S. segment refers to the company’s U.S. and Puerto Rico-based stores and revenue from its U.S. based wholesale business. The Children’s Place International segment is involved in the Canadian-based stores, revenue from the company’s Canadian-based wholesale business, as well as revenue from international franchisees. The company was founded by David Pulver and Clinton A. Clark in 1969 and is headquartered in Secaucus, NJ.

Childrens Place Inc

Children's Place is trending as investors digest recent earnings, which included a revenue beat and signs of progress in their turnaround plan, though offset by tariff concerns. The community is actively discussing the potential for a short squeeze, fueled by high short interest and positive momentum from the turnaround initiatives. Optimism surrounds the company's transformation plan and potential for profitability in upcoming quarters.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapport Therapeutics is trending due to its recent IPO and after-hours trading activity, with community members pointing to upcoming data from their RAP-219 Phase 2a trial as a potential catalyst. Discussions revolve around the stock's low float and potential for volatility, as well as debate over its valuation in comparison to others in the biotechnology space. Some traders speculate about a possible short squeeze, while others express skepticism about the company's long-term prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates

Codexis (CDXS) delivered earnings and revenue surprises of +5.88% and +2.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of -6.52% and -52.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates

Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of -14.46% and -66.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Vertex Pharmaceuticals (VRTX) Surpasses Q2 Earnings and Revenue Estimates

Vertex (VRTX) delivered earnings and revenue surprises of +6.60% and +2.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates

Regeneron (REGN) delivered earnings and revenue surprises of +60.52% and +9.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates

Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates

Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates

Crosswalk Therapeutics Announces Acquisition of Rare Disease Assets from Codexis, Inc.

Crosswalk Therapeutics Announces Acquisition of Rare Disease Assets from Codexis, Inc. Crosswalk Therapeutics Announces Acquisition of Rare Disease Assets from Codexis, Inc. PR Newswire CAMBRIDGE...

Codexis, Inc. (NASDAQ:CDXS) Sees Significant Decrease in Short Interest

Codexis, Inc. (NASDAQ:CDXS - Get Free Report) was the target of a significant decrease in short interest in March. As of March 15th, there was short interest totalling 2,290,000 shares, a decrease of...

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.

CDXS
Codexis Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CDXS News

CDXS Codexis Inc.